Clinical experience of using herbal medicinal product Glucemedin in the comprehensive treatment of patients with type 2 diabetes mellitus
Background. The current task of treating patients with type 2 diabetes mellitus and dyslipoproteinemia is the analysis of efficiency of the combination of standard hypoglycemic agents with phytotherapeutic drugs, but information about the feature of their use requires clarification. The purpose was to evaluate the influence of treatment with a fixed combination of gymnema, banaba leaves and bitter melon extract together with sulfonylurea and metformin on the dynamics of the clinical state, carbohydrate and lipid metabolism in patients with diabetes mellitus type 2. Materials and methods. The study involved 40 patients (16 men) aged 61.7 ± 7.8 years with type 2 diabetes. All patients before the treatment and after 2 months underwent: general blood test, evaluation of glycated hemoglobin, creatinine, urea, bilirubin, alanine aminotransferase, aspartate aminotransferase, cholesterol, high-density lipoproteins, low-density lipoproteins, triglyce-rides, glucose levels. All patients were divided into four groups according to the basic hypoglycemic therapy: group 1 received metformin (n = 6); group 2 — metformin and gliclazide (n = 10); group 3 — metformin and glimepiride (n = 14). The dose of hypoglycemic drugs was not changed during the whole study, Glucemedin was additionally administered in a dose of 1 capsule three times a day during 2 months. In group 4 (controls; n = 10), standard hypoglycemic therapy was not modified. Results. The inclusion of Glucemedin in the treatment resulted in a statistically significant decrease in the level of glycemia, glycated hemoglobin, triglycerides and an increase in high-density lipoproteins, and did not affect the concentration of total cholesterol and low-density lipoproteins. Conclusions. The obtained results demonstrated that the efficacy of combining standard hypoglycemic therapy with Glucemedin are consequent of the interacting impact of these pharmacological agents on the investigated parameters, which justifies the expediency of its use in the treatment of patients with type 2 diabetes mellitus.
Full Text:PDF (Українська)
World Health Organization. The top 10 causes of death. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: May 24, 2018.
Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9. doi: 10.1016/S0140-6736(06)69701-8.
Uma Makheswari M, Sudarsanam D. Phytomedicine for diabetes mellitus: an overview. Research in Pharmacy. 2011;1(4):28-37.
American Society of Hospital Pharmacists (ASHP). AHFS Drug information 2018. Authority of the Board of the American Society of Health-System Pharmacists, American Hospital Formulary Service. Bethesda, Md, USA; 2012. 3840 p.
Serghiyenko VA, Serghiyenko AA. Diabetychna kardiovaskuljarna avtonomna nejropatija: monografija [Diabetic cardiovascular autonomic neuropathy: monograph]. Lviv: Lviv National Medical University; 2016. 268 p. (in Ukrainian).
Valensi P. Cardiovascular autonomic neuropathy. In: McGuire DK, Marx N, editors. Diabetes in cardiovascular disease: A companion to braunworld’s heart disease. Amsterdam: Elsevier Saunders; 2015. 361-368 pp.
Kotseva K, Jennings C, De Bacquer D, De Backer G, Keil U, Wooda D. 1349 EUROASPIRE III: Lifestyle and risk factor management and use of drug therapies in coronary patients from 22 countries in Europe. Eur J Cardiovasc Nurs. 2008;7(1 Suppl):28. doi: 10.1016/J.EJCNURSE.2008.01.049.
Thakur GS, Sharma R, Sanodiya BS, Pandey M, Prasad GBKS and Bisen PS. Gymnema sylvestre: an alternative therapeutic agent for management of diabetes. Journal of Applied Pharmaceutical Science. 2012 Dec;2(12):1-6. doi: 10.7324/JAPS.2012.21201.
Ulbricht C, Abrams TR, Basch E, et al. An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Sep;8(3):311-30. doi: 10.3109/19390211.2011.597977.
Miura T, Takagi S, Ishida T. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Evid Based Complement Alternat Med. 2012;2012:871495. doi: 10.1155/2012/871495.
Inayat U Rahman, Khan RU, Khalil Ur Rahman, Bashir M. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J. 2015 Jan 26;14:13. doi: 10.1186/1475-2891-14-13.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019